drug · antibody
bevacizumab
Phase 3updated 5mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 8- tagOncology11 co-mentions · 4 sources
- tagRecall6 co-mentions · 4 sources
- drugGP-25 co-mentions · 3 sources
- drugbevacizumab biosimilar5 co-mentions · 3 sources
- tagColorectal Cancer3 co-mentions · 2 sources
- companyIRCCS Foundation National Cancer Institute1 co-mentions · 1 sources
- companyBeijing Bethune Charitable Foundation1 co-mentions · 1 sources
- companyUniversity of Texas MD Anderson Cancer Center1 co-mentions · 1 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 20 approved and 146 investigational indications.
indications
indications
NSCLCMelanomaDiabetic Macular Edema
targets
Vascular endothelial growth factor A, long form
all catalysts(5)
phase 1 2 completion · 1
phase 1 2 initiation · 1
phase 1 completion · 1
phase 2 3 completion · 1
Trials studying bevacizumab
- phase1The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
- phase1A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- phase3A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- phase2A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- phase3A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- phase3Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
- phase3Evaluating Novel Therapies in ctDNA Positive GI Cancers
- phase1A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
News(10)
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s ElahereGenmab has linked an antibody-drug conjugate to a median progression-free survival of 9.5 months, leading TD Cowen analysts to hail the asset as “clearly superior” to AbbVie’s Elahere.fiercebiotech · 2d ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 9d ago
- Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugsRoche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.fiercebiotech · 13d ago
- Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…fiercebiotech · 1mo ago
- TME holds onto $1B dream for brain cancer drug as search for partners nears conclusionTME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings to its hope of generating $1 billion in peak sales from the asset.fiercebiotech · 1mo ago
- Vaderis hauls in $152M to test an AKT-targeting drugThe startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.biopharma_dive · 1mo ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 2mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 5mo ago
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 5mo ago
- Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCCSimlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.onclive · 5mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that